Published in Cancer Res on February 15, 2006
To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest (2008) 3.05
TRAIL in cancer therapy: present and future challenges. Expert Opin Ther Targets (2007) 1.36
Targeting the Anti-Apoptotic Protein c-FLIP for Cancer Therapy. Cancers (Basel) (2011) 1.25
The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood (2010) 1.24
c-FLIP, a master anti-apoptotic regulator. Exp Oncol (2012) 1.24
Anticancer agents that counteract tumor glycolysis. ChemMedChem (2012) 1.17
Targeting the metabolic microenvironment of tumors. Adv Pharmacol (2012) 1.11
The Warburg effect: evolving interpretations of an established concept. Free Radic Biol Med (2014) 1.07
The marine lipopeptide somocystinamide A triggers apoptosis via caspase 8. Proc Natl Acad Sci U S A (2008) 1.05
Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis. Cell Death Differ (2012) 1.00
A cell-based high-throughput screen to identify synergistic TRAIL sensitizers. Cancer Immunol Immunother (2008) 0.98
Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy. Clin Cancer Res (2012) 0.96
4-(4-Chloro-2-methylphenoxy)-N-hydroxybutanamide (CMH) targets mRNA of the c-FLIP variants and induces apoptosis in MCF-7 human breast cancer cells. Mol Cell Biochem (2010) 0.88
Inhibition of SREBP1 sensitizes cells to death ligands. Oncotarget (2011) 0.86
Metabolic adaptation to chronic inhibition of mitochondrial protein synthesis in acute myeloid leukemia cells. PLoS One (2013) 0.80
A novel formulation of tigecycline has enhanced stability and sustained antibacterial and antileukemic activity. PLoS One (2014) 0.80
Opportunities and challenges in combination gene cancer therapy. Adv Drug Deliv Rev (2015) 0.78
Carbon nanotubes induce apoptosis resistance of human lung epithelial cells through FLICE-inhibitory protein. Toxicol Sci (2014) 0.78
A humanized leucine zipper-TRAIL hybrid induces apoptosis of tumors both in vitro and in vivo. PLoS One (2015) 0.76
Anticancer agents interacting with membrane glucose transporters. Medchemcomm (2016) 0.75
Droxinostat, a Histone Deacetylase Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cell Lines via Activation of the Mitochondrial Pathway and Downregulation of FLIP. Transl Oncol (2016) 0.75
Targeted TPX2 increases chromosome missegregation and suppresses tumor cell growth in human prostate cancer. Onco Targets Ther (2017) 0.75
An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (2005) 22.40
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet (2004) 12.25
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell (2006) 8.59
Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest (2005) 8.45
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature (2009) 8.44
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol (2008) 7.89
Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov (2008) 7.64
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37
The NLR gene family: a standard nomenclature. Immunity (2008) 4.77
Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology (2009) 4.72
Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum (2002) 4.69
Bcl-2-mediated alterations in endoplasmic reticulum Ca2+ analyzed with an improved genetically encoded fluorescent sensor. Proc Natl Acad Sci U S A (2004) 4.46
Reconstituted NALP1 inflammasome reveals two-step mechanism of caspase-1 activation. Mol Cell (2007) 4.33
Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum (2002) 4.23
Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell (2004) 4.00
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood (2008) 3.67
Predictors of infection in rheumatoid arthritis. Arthritis Rheum (2002) 3.47
Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents. J Clin Oncol (2006) 3.31
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med (2010) 3.26
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol (2007) 3.23
Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell (2004) 3.14
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood (2006) 3.13
Measured and estimated GFR in healthy potential kidney donors. Am J Kidney Dis (2004) 3.11
ER stress-induced cell death mechanisms. Biochim Biophys Acta (2013) 3.07
BAX inhibitor-1 is a negative regulator of the ER stress sensor IRE1alpha. Mol Cell (2009) 3.07
MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood (2005) 2.88
Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol (2005) 2.83
An IAP-IAP complex inhibits apoptosis. J Biol Chem (2004) 2.82
Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest (2009) 2.80
Bcl-2 and Bcl-XL regulate proinflammatory caspase-1 activation by interaction with NALP1. Cell (2007) 2.79
Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol (2009) 2.78
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst (2008) 2.77
Apoptosis-based therapies for hematologic malignancies. Blood (2005) 2.77
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov (2013) 2.74
Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell (2011) 2.68
Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature (2003) 2.66
Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem (2003) 2.64
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood (2006) 2.63
Quality of reporting of modern randomized controlled trials in medical oncology: a systematic review. J Natl Cancer Inst (2012) 2.57
Medication reconciliation at hospital discharge: evaluating discrepancies. Ann Pharmacother (2008) 2.57
Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol (2005) 2.52
MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood (2010) 2.49
HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J (2003) 2.47
Birc2 (cIap1) regulates endothelial cell integrity and blood vessel homeostasis. Nat Genet (2007) 2.47
Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer. J Natl Cancer Inst (2012) 2.46
Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood (2006) 2.45
Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2012) 2.45
Impact of wait times on survival for women with uterine cancer. J Clin Oncol (2013) 2.45
Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res (2003) 2.43
Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia. Nat Med (2007) 2.38
Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood (2005) 2.37
Discovery of a viral NLR homolog that inhibits the inflammasome. Science (2011) 2.36
BI-1 regulates an apoptosis pathway linked to endoplasmic reticulum stress. Mol Cell (2004) 2.32
Apoptosis-inducing factor triggered by poly(ADP-ribose) polymerase and Bid mediates neuronal cell death after oxygen-glucose deprivation and focal cerebral ischemia. J Neurosci (2005) 2.32
Selective disruption of lysosomes in HeLa cells triggers apoptosis mediated by cleavage of Bid by multiple papain-like lysosomal cathepsins. J Biol Chem (2003) 2.30
Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc Natl Acad Sci U S A (2008) 2.26
The PAAD/PYRIN-only protein POP1/ASC2 is a modulator of ASC-mediated nuclear-factor-kappa B and pro-caspase-1 regulation. Biochem J (2003) 2.25
The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res (2002) 2.24
Heterotypic interactions among NACHT domains: implications for regulation of innate immune responses. Biochem J (2004) 2.23
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res (2006) 2.23
Advances in molecular labeling, high throughput imaging and machine intelligence portend powerful functional cellular biochemistry tools. J Cell Biochem Suppl (2002) 2.14
Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood (2002) 2.14
Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L). Chem Biol (2004) 2.03
Randomized phase II trials: inevitable or inadvisable? J Clin Oncol (2010) 2.02
Apoptosis-associated speck-like protein containing a caspase recruitment domain is a regulator of procaspase-1 activation. J Immunol (2003) 2.02
Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood (2009) 1.99
Heat-shock proteins as regulators of apoptosis. Oncogene (2003) 1.97
XIAP mediates NOD signaling via interaction with RIP2. Proc Natl Acad Sci U S A (2009) 1.95
A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. Clin Cancer Res (2006) 1.92
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol (2007) 1.91
Identification and characterization of a novel bacterial virulence factor that shares homology with mammalian Toll/interleukin-1 receptor family proteins. Infect Immun (2006) 1.91
BAG3 deficiency results in fulminant myopathy and early lethality. Am J Pathol (2006) 1.90
PAN1/NALP2/PYPAF2, an inducible inflammatory mediator that regulates NF-kappaB and caspase-1 activation in macrophages. J Biol Chem (2004) 1.89
Mitochondrial ceramide-rich macrodomains functionalize Bax upon irradiation. PLoS One (2011) 1.86
Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res (2003) 1.83
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol (2009) 1.83
Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia. Leuk Lymphoma (2012) 1.80
Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene (2005) 1.80
The PAAD/PYRIN-family protein ASC is a dual regulator of a conserved step in nuclear factor kappaB activation pathways. J Exp Med (2002) 1.76
Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancer Ther (2006) 1.74
Dermopathy of Graves' disease (pretibial myxedema): long-term outcome. J Clin Endocrinol Metab (2002) 1.73
Differential regulation of Bax and Bak by anti-apoptotic Bcl-2 family proteins Bcl-B and Mcl-1. J Biol Chem (2008) 1.72
Activated, but not resting, T cells can be recognized and killed by syngeneic NK cells. J Immunol (2003) 1.72
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood (2013) 1.70
Distinct BIR domains of cIAP1 mediate binding to and ubiquitination of tumor necrosis factor receptor-associated factor 2 and second mitochondrial activator of caspases. J Biol Chem (2005) 1.69
Drug Repurposing from an Academic Perspective. Drug Discov Today Ther Strateg (2011) 1.68
Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res (2007) 1.67
Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. Cancer Res (2005) 1.66
A short Nur77-derived peptide converts Bcl-2 from a protector to a killer. Cancer Cell (2008) 1.66
Evolutionarily conserved cytoprotection provided by Bax Inhibitor-1 homologs from animals, plants, and yeast. Gene (2003) 1.65
Lymphocyte-specific TRAF3 transgenic mice have enhanced humoral responses and develop plasmacytosis, autoimmunity, inflammation, and cancer. Blood (2008) 1.65